Navigation Links
New tool to assess excessive daytime sleepiness in adolescents published in JCSM
Date:10/15/2007

WESTCHESTER, Ill. A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) features the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure excessive daytime sleepiness in adolescents.

The study, led by James C. Spilsbury, PhD, of the Division of Clinical Epidemiology and Biostatistics in Cleveland, Ohio, focused on a subsample of 411 adolescents between 11-17 years of age, who were recruited from area schools and churches, as well as a second subsample of 62 adolescents with a diagnosed sleep related breathing disorder, all of whom completed the CASQ along with two other surveys measuring daytime sleepiness and other sleep parameters (sleep duration on school nights, sleep duration on non-school nights, and sleep debt). The third source of adolescents for the sample consisted of participants in a community-based cohort study (Cleveland Sleep and Health Study) who did not have evidence of a sleep related breathing disorder by objective overnight polysomnographic monitoring or reported snoring.

According to the study, the CASQs internal consistency was good. Correlations between the CASQ and the two other surveys measuring daytime sleepiness and sleep parameters gave preliminary evidence of the CASQs construct validity based on the following findings:

  • Greater CASQ scores, reflecting increased daytime sleepiness, were significantly associated with decreased sleep duration in both normative and sleep disorder samples, as well as with increased sleep debt in the normative sample.

  • CASQ scores were positively correlated with age.

  • The CASQ displayed convergent validity by its strong positive correlations with the two other surveys measuring daytime sleepiness and other sleep parameters.

  • Adolescents with a sleep related breathing disorder had higher CASQ scores than adolescents without a sleep related breathing disorder.

  • The CASQ detected differences in daytime sleepiness between both normal controls and primary snorers, and between normal controls and adolescents with OSA.

  • In contrast to the CASQ, one of the two other surveys did not detect significant differences in sleepiness between adolescent controls and those with OSA, while the second survey did not detect differences between primary snorers and controls.

  • The CASQ was associated with objective measures derived from the polysomnograms, or a sleep test.

The CASQ shows promise as a valid measure of daytime sleepiness in adolescents, said Dr. Spilsbury, who added that future research should examine the association between the CASQ and additional objective measures of sleepiness and sleep duration, as well as the inclusion of participants with greater social and ethnic diversity and those with other sleep disorders or problems.

Administering the CASQ to groups of adolescents with other known sleep disorders would provide additional information about clinically significant score cut-off points. Having a brief, valid and inexpensive measure of daytime sleepiness at their disposal would enable clinicians to avoid the more costly and burdensome multiple sleep latency test. Such an instrument could also be used as a simple, inexpensive way to monitor patient responses to treatment for sleep problems or disorders, added Dr. Spilsbury.


'/>"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Researchers Scale to assess the Severity of Epilepsy in Kids
2. Assessment for hearing aid implants in the process
3. Time to re-assess lung donation concept
4. Nurses competing with junior doctors in some assessments
5. Assessing Prostate Cancer Risk
6. Scientists Developed Cheap Way To Assess Sleep
7. Risk of colon cancer to be assessed by simple blood test
8. Scorecard to help in diabetic risk assessment of the Indian Population
9. Scorecard to help in diabetic risk assessment of the Indian Population
10. New technique to assess risk of fracture
11. Ofcom To Assess The Bedside Call Charges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... of Proctology) announced today the opening of 3 medical offices specializing specifically ... Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, ...
(Date:1/18/2017)... ... 18, 2017 , ... A recent video posting of a new fidget product ... of fidgeting to relieve stress and anxiety. No one was more surprised than ... had just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: